ABCB1 and myopathy: Modification of transporter function by genetic factors (e.g. SLCO1B1 polymorphisms and simvastatin-induced myopathies) [11] and concomitantly administered drugs [e.g. inhibitors of OCTs/MATEs or inhibitors/inducers of P-glycoprotein (P-gp, ABCB1)] contributes to interindividual variability in drug exposure and effects [10].